167 related articles for article (PubMed ID: 11367188)
1. New FDA rules force drug makers to detail youth-specific effects. Food and Drug Administration.
Newsline People AIDS Coalit N Y; 1999 Jan; ():34. PubMed ID: 11367188
[TBL] [Abstract][Full Text] [Related]
2. FDA clarifies rules, allows combining antiretrovirals in clinical trials. Food and Drug Administration.
AIDS Treat News; 1999 Nov; (No 331):5-6. PubMed ID: 11367127
[TBL] [Abstract][Full Text] [Related]
3. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
[TBL] [Abstract][Full Text] [Related]
4. Issues in the design of clinical trials for safety in HIV-infected children.
Lindsey JC; Kline MW
Pediatr AIDS HIV Infect; 1996 Apr; 7(2):69-82. PubMed ID: 11361484
[TBL] [Abstract][Full Text] [Related]
5. FDA publishes conflict of interest rules for clinical trials. Food and Drug Administration.
James JS
AIDS Treat News; 1998 Mar; (No 290):8. PubMed ID: 11365123
[TBL] [Abstract][Full Text] [Related]
6. Sunscreen drug products for over-the-counter human use; final monograph. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 May; 64(98):27666-93. PubMed ID: 10558542
[TBL] [Abstract][Full Text] [Related]
7. FDA news. Food and Drug Administration.
Res Initiat Treat Action; 1999 Jan; 5(1):20. PubMed ID: 11366229
[TBL] [Abstract][Full Text] [Related]
8. Regulatory issues in pediatric psychopharmacology.
Laughren TP
J Am Acad Child Adolesc Psychiatry; 1996 Oct; 35(10):1276-82. PubMed ID: 8885581
[TBL] [Abstract][Full Text] [Related]
9. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
Cowden AL; Katz KA
Br J Dermatol; 2006 May; 154(5):950-8. PubMed ID: 16634900
[TBL] [Abstract][Full Text] [Related]
10. New pediatric dosage rules: information and testing.
Feeg VD
Pediatr Nurs; 1998; 24(6):518, 613. PubMed ID: 10085992
[No Abstract] [Full Text] [Related]
11. Symptom-reduction trials at FDA clinical trials workshop. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Sep; (no 231):7. PubMed ID: 11362873
[TBL] [Abstract][Full Text] [Related]
12. Changing requirements for evaluation of pharmacologic agents.
Chesney RW; Christensen ML
Pediatrics; 2004 Apr; 113(4 Suppl):1128-32. PubMed ID: 15060209
[TBL] [Abstract][Full Text] [Related]
13. IRB/FDA requirements relevant to HIV/AIDS clinical trials in correctional settings.
Cohen J;
AIDS Read; 2001 Jan; 11(1):41-2. PubMed ID: 11215087
[TBL] [Abstract][Full Text] [Related]
14. FDA transparency rules could hit small companies hardest.
Allison M
Nat Biotechnol; 2010 Aug; 28(8):767-8. PubMed ID: 20697386
[No Abstract] [Full Text] [Related]
15. Prescription drug products that require patient package inserts; ampicillin and phenytoin--Food and Drug Administration. Final rule.
Fed Regist; 1981 Jan; 46(1):28. PubMed ID: 10249520
[TBL] [Abstract][Full Text] [Related]
16. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.
Huang SM; Temple R; Throckmorton DC; Lesko LJ
Clin Pharmacol Ther; 2007 Feb; 81(2):298-304. PubMed ID: 17259955
[TBL] [Abstract][Full Text] [Related]
17. FDA notifications. FDA approves label change for nevirapine.
AIDS Alert; 2008 Aug; 23(8):91-2. PubMed ID: 18724490
[No Abstract] [Full Text] [Related]
18. Switchability of neoral and equoral according to Food and Drug Administration rules and regulations.
Masri MA; Haberal M; Rizvi A; Stephan A; Bilgin N; Naqvi A; Barbari A; Kamel G; Zafar N; Emiroğlu R; Colak T; Manzoor K; Matha V; Kamarad V; Rost M; Rizk S; Hazime A; Perlik F
Transplant Proc; 2005 Sep; 37(7):2988-93. PubMed ID: 16213282
[TBL] [Abstract][Full Text] [Related]
19. FDA gives salvage therapy testing a push forward.
Bass E
AIDS Treat News; 2001 Mar; (362):3-7, 1. PubMed ID: 11569956
[TBL] [Abstract][Full Text] [Related]
20. Prescription drugs; revocation of final guideline patient package inserts and withdrawal of draft guideline patient package inserts--Food and Drug Administration. Notice.
Fed Regist; 1982 Sep; 47(173):39249-50. PubMed ID: 10258155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
